In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Predicting the development of cardiogenic shock in myocardial infarction

Session Poster Session 1

Speaker Irina Sukmanova

Event : Heart Failure 2016

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure - Other
  • Session type : Poster Session

Authors : I Sukmanova (Barnaul,RU), OST Olga Tanana (Barnaul,RU)

Authors:
I Sukmanova1 , OST Olga Tanana1 , 1Altay region cardiologist hospilal, acute infarction - Barnaul - Russian Federation ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2016 ) 18 ( Supplement 1 ), 132

Purpose: to develop a mathematical formula to calculate the risk of developing cardiogenic shock in patients with AMI. Methods: we examined 55 patients with mi aged 56-85 years. The first group consisted of 29 patients (14 men and 15 women) at the age of 66,8 ± 1.2 years, complicated by cardiogenic shock, second - 26 patients (15 men and 11 women) at the age of 66,4 ± 1,0 years without cardiogenic shock. All admission underwent standard laboratory tests with dynamic assessment of the level of troponin I, D-dimer. Repeatedly recorded 12-lead ECG was performed the echocardiography, the coronary angiography on the unit of General Electric, was measured central hemodynamic parameters. The Results: Patients in compared groups were matched for age, both groups were dominated by men. In the first and second groups of more than 60% of patients with IMPT (at 65.5% and 61.5%, respectively, p < 0.05). Patients with back, they were almost 2 times more in the 1st group (CABG) than in the second (10 (34,4%), against 5(19,2%), with 2/3 of them involved the right ventricle. More than 60% (62,2%) patients in the CABG group and 61.5% in the group without CABG was performed revascularization ISA. The "symptom-balloon" in the group with CABG when INT was 2 times longer and amounted to 420 minutes than in those without CABG (210, p < 0.05), which was an important factor determining the development of complications. Thrombolytic therapy is carried out 10 (52,6%) patients with INT in the 1st group and 6 (37,5%) patients of the second group. PCI completed 18(62%) patients of the first group and 14(53.8 percent) in the second. Pharmacoinvasive strategy (TLT + PCI) due to non-delivery of the patient in the first 120 minutes were used in 5(27,2%) patients of the first group and 4(15.4 %) second. Most patients of the 1st group, they developed in the first day, admission CABG were signs in 8(27.5%) patients. The garden in the first group at admission was less than during the second (96.5 % against 138.4, p < 0.01). To predict the development of shock on the obtained data was applied stepwise discriminant analysis selected the most important predictors of the development of CABG. For these factors amounted to equations linear discriminating functions for each group. To predict outcome in new patients of the equation 2 is calculated: Shock(+) = -308,4 + 0,22*AD(p) + 4,47*Sat + 0,44*GFR - 0,32*Troponin + 0,61*Creatinine - 0,0011* income + 6,37* Potassium + 0,37* Glucose + 0,32* Hemoglobin; Shock(-) = -288,0 + 0,16*AD(p) + 4,21*Sat + 0,49*GFR - 0,22*Troponin + 0,66*Creatinine - 0,0014* income + 7,66* Potassium + 0,28* Glucose + 0,29* Hemoglobin. Each patient can be assigned to the group corresponding to the maximum value of the function, with a probability of 83.6 per cent. Conclusions: Thus, a multivariate mathematical model based on the method of discriminant analysis to predict the development of shock.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are